Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
In Reply: Dr El-Sohemy comments on recent findings
that pravastatin does not stimulate bone formulation in vitro by increasing
BMP-2. This mechanism is a current focus of interest in the search of a possible
pharmacologic explanation for the observed effect of statins on bone, but
it is not yet proven.
We stratified statin users and assessed the risk of having a fracture
in association with current exposure to simvastatin or pravastatin, the 2
statins most often used in our study sample. Compared with nonusers of any
lipid-lowering drugs, ORs for current use of simvastatin (90 patients and
671 controls) and pravastatin (10 patients and 131 controls) were 0.61 (95%
confidence interval [CI], 0.47-0.79) and 0.34 (95% CI, 0.17-0.65), respectively.
There was insufficient cholestyramine use in our sample to perform a separate
analysis of its effect on fractures.
Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. Statin Drugs and the Risk of Fracture—Reply. JAMA. 2000;284(15):1921-1922. doi:10.1001/jama.284.15.1921